Global Footprint InClin operates from the United States with a Sydney office, enabling global trials across North America and APAC. This presence helps sponsors navigate local regulatory requirements and speed up site activation. The single source model reduces vendor management and is appealing for multinational studies seeking consistent timelines. Sales opportunities include targeting sponsors with cross border trials needing global execution and regulatory support.

Full Service Advantage InClin provides an integrated suite of services across phases from project management and data management to biostatistics, programming, safety, medical writing and strategic consulting. This reduces vendor fragmentation, accelerates timelines and helps control costs. The breadth enables upsell across trial phases and tighter sponsor oversight. The partnership offers a streamlined procurement and execution process for complex trials.

Team Continuity The staff average over twenty years of clinical research experience and a high retention rate ensure the same team can design and complete trials, reducing knowledge transfer gaps. With more than 150 sponsor relationships and over 400 trials completed, InClin delivers proven continuity. This stability is particularly valuable for long duration Phase 2 and 3 programs and regulatory submissions.

Regulatory Excellence InClin maintains a rigorous quality assurance framework aligned with FDA and EMA requirements and emphasizes proactive, transparent sponsor communication. This makes them well suited for regulated, data sensitive trials and for NDAs, sNDA and BLAs.

Leadership Partnerships Leadership investments including a vice president of clinical operations and a senior vice president of biometrics, plus collaboration events with major sponsors such as GSK, signal a growth oriented culture and strong biometrics and data science capabilities. With a track record of sponsor partnerships, InClin is positioned to collaborate on strategic trials, co development and expand with new sponsors in biotech and pharmaceutical sectors.